Defining Value for the Treatment of Brain Metastases in Metastatic HER2-Positive Breast Cancer

Examining current treatment options for brain metastases in metastatic HER2+ breast cancer and assessing the clinical and economic burden.
EP 1: Progression of HER2+ mBC

Sarah Sammons, MD, provides an overview of the progression HER2-positive metastatic breast cancer [mBC] and common areas for the development of metastases, including in the brain.

EP 2: HER2+ mBC: Diagnosing Patients With Brain Mets

Insights on diagnosing patients who have HER2+ metastatic breast cancer with brain metastases based on current NCCN Guidelines recommendations when they may present with them during the course of treatment, and the impact on quality of life.

EP 3: Monitoring Brain Mets in HER2+ mBC

Kevin M. Kalinsky, MD, MS, discusses monitoring patients with HER2-positive mBC who have asymptomatic brain metastases and advancements in therapy for HER2-positive disease leading to increased brain metastases.

EP 4: Healthcare Utilization for HER2+ mBC With Brain Mets

Sarah Sammons, MD, and Bhavesh Shah, RPh, BCOP, discuss the increase in health care resource utilization associated with brain metastases for HER2-positive mBC.

EP 5: Treatment Beyond Second-line Therapy in HER2+ mBC

Exploring current advances in treatment options beyond the second-line setting for progressive HER2-positive metastatic breast cancer.

EP 6: Managing At-Risk Patients for Brain Mets in HER2+ mBC

The goals of therapy and unmet needs for patients with HER2-positive metastatic breast cancer at risk for brain metastases are examined.

EP 7: HER2CLIMB Study

A review of the HER2CLIMB study using oral the TKI tucatinib as therapy for HER2-positive metastatic breast cancer.

EP 8: Phase 2 LANDSCAPE Trial

Sarah Sammons, MD, and Kevin M. Kalinsky, MD, MS, review the phase 2 LANDSCAPE trial using lapatinib for patients with HER2+ mBC and a history of brain metastases.

EP 9: Phase 3 NALA Study

A review of the NALA study looking at the use of capecitabine plus neratinib in patients with pretreated metastatic HER2-positive breast cancer.

EP 10: Phase 2 DESTINY-Breast01 Trial

Kevin M. Kalinsky, MD, MS, and Sarah Sammons, MD, review the phase 2 single-arm trial DESTINY-Breast01, exploring the use of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer.

EP 11: Value of Emerging Agents in HER2+ mBC

Bhavesh Shah, RPh, BCOP, defines the value for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer.

EP 12: Sequencing HER2-targeted Agents in mBC

Comparing and contrasting the safety and efficacy of agents when approaching treatment of brain metastases in HER2-positive mBC.

EP 13: Approaching At-Risk Patients for Brain Mets in HER2+ mBC

A payer and provider perspective on treating all patients with HER2-positive mBC as if they are at risk for brain metastases and the use of clinical pathways to ensure the correct patients are treated.

EP 14: Impact of Early Identification of Brain Mets

A payer perspective on the impact of early identification of brain mets in HER2+ metastatic breast cancer on healthcare utilization and patient outcomes as well as recommendations to other payers managing this patient population.

EP 15: Patient-Centered Care for Treatment of Brain Mets

The role of patient-centered value-based care models in the treatment of brain metastases in HER2+ mBC and the importance of patient support services.

EP 16: Payer Perspective: Impact of COVID-19 on Treatment of mBC

Bhavesh Shah, RPh, BCOP, provides a payer perspective on the impact of COVID-19 on site of care for patients with metastatic breast cancer and the role of value-based contracting for the future.

EP 17: Impact of COVID-19 and Future of mBC Treatment

The impact of COVID-19 on the treatment of metastatic breast cancer in regard to site of care and utilization of telehealth, as well as the evolving treatment landscape with emerging agents in the pipeline.